Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera

NCT ID: NCT01193699

Last Updated: 2018-01-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-08-31
• Study Completion Date: 2018-01-25

Brief Summary

The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and biomarker modulation will be performed.

Conditions

Polycythemia Vera

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

P1101

Group Type: EXPERIMENTAL

PEG-P-INF alpha-2b (P1101)

Intervention Type: DRUG

µg (starting with 50 µg), subcutaneously, 2-weekly administration

Interventions

PEG-P-INF alpha-2b (P1101)

µg (starting with 50 µg), subcutaneously, 2-weekly administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Written informed consent obtained prior to any study specific screening activities and able to comply with this protocol.

2. Patients age ≥18 years

3. Confirmed diagnosis of PV according to either the WHO criteria (2008, appendix 6) or the PSVG (appendix 7) criteria plus JAK-2 positivity, including newly diagnosed, pre-treated and on cytoreductive therapy.

4. Eastern Cooperative Oncology Group performance status ≤ 2

5. If female of childbearing potential - have a negative urine pregnancy test result within 7 days prior to the scheduled first application of investigational product and agree to employ adequate birth control measures for the duration of the study.

Exclusion Criteria

1. Diagnosis of any other myeloproliferative disorder

2. Any clinically significant illness or surgery within 4 weeks prior to dosing

3. Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening

4. Uncontrolled hypertension (systolic > 150 mmHg and diastolic > 100 mmHg, or clinically significant (i.e. active) cardiovascular disease: CVA/stroke (≤ 3 months prior to enrolment), myocardial infarction (≤ 3 months prior to enrolment), significant coronary artery stenosis, unstable angina, New York Heart Association (NYHA) Class 2 or greater Congestive heart failure, or serious cardiac arrhythmia requiring medication.

5. Previous treatment with Interferon for PV

6. Concurrent treatment with cytoreductive agents other than Hydroxyurea and investigational agents of any type

7. History of malignant disease, including solid tumours and haematological malignancies (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that have been completely excised and are considered cured) within the last 3 years

8. History of severe allergic (like anaphylaxis) or hypersensitivity reactions (like angioedema), any known or suspected intolerance to the investigational product.

9. Use of any investigational drug or participation in any investigational drug study within the last 4 weeks

10. Clinically significant history or known presence of psychiatric disorders, including but not limited to depression, anxiety and sleep disorders

11. Organ transplant, past or planned

12. Inadequate liver function defined by serum (total) bilirubin > 2,5 x ULN and/ or AST and ALT > 2,5 x ULN

13. Clinically significant ECG findings

14. History of renal disease requiring haemodialysis or seizure disorder requiring anticonvulsant therapy

15. Pregnant or lactating females (pregnancy test to be assessed within 7 days prior to study treatment start)

16. Acute or chronic infections or autoimmune diseases (collagen diseases, polyarthritis, immune thrombocythemia, thyroiditis, psoriasis, lupus nephritis or any other autoimmune disorder).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AOP Orphan Pharmaceuticals AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Barbara Grohmann-Izay, MD

Role: STUDY_DIRECTOR

AOP Orphan Pharmaceuticals AG

Locations

Innsbruck, Tyrol, Austria

Wels, Upper Austria, Austria

Salzburg, , Austria

Vienna, , Austria

Vienna, , Austria

Vienna, , Austria

Countries

Austria

References

Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10.

Reference Type: DERIVED

PMID: 26261238 (View on PubMed)

Other Identifiers

P11012010

Identifier Type: -

Identifier Source: org_study_id